• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      The Swedish Council on Health Technology Assessment (SBU)
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [25471 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tivozanib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tivozanib (renal cell carcinoma) - Addendum to Commission A17-58]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisotumab vedotin (cervical cancer) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (squamous NSCLC, first line) – benefit assessment according to §35a Social Code Book (SGB) V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (small cell lung cancer, extensive stage) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (oesophageal squamous cell carcinoma, second line) – benefit assessment according to § 35a Social Code Book (SGB) V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (oesophageal squamous cell carcinoma, first line) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (oesophageal squamous cell carcinoma, first line) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (NSCLC, second line) - benefit assessment according to § 35a Social Code Book (SGB) V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (NSCLC, second line or later) – Addendum to Project A24-128]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (non-squamous NSCLC) - benefit assessment according to §35a Social Code Book (SGB) V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (nasopharyngeal carcinoma) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (gastric or gastroesophageal junction adenocarcinoma, HER2-negative) – benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisagenlecleucel (follicular lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisagenlecleucel (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisagenlecleucel (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisagenlecleucel (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisagenlecleucel (B-cell acute lymphoblastic leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisagenlecleucel (B-cell acute lymphoblastic leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisagenlecleucel (ALL) – Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tirzepatide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tirzepatide (type 2 diabetes mellitus) – Addendum to Project A23-112]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tirzepatide (type 2 diabetes mellitus in children and adolescents)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tirbanibulin (actinic keratosis) - Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tiratricol (Allan-Herndon-Dudley syndrome) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tiotropium/olodaterol - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tiotropium/olodaterol - Addendum to Commission A15-31]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tiotropium bromide in the treatment of chronic obstructive pulmonary disease]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Timing of myocardial contraction and relaxation mapped with high temporal resolution MRI tagging and 3-D strain analysis: detection of ventricular dyssynchrony and prediction of response to biventricular pacing]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tildrakizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2018     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [TIDY program. Therapeutic Identification of depression in Young people.]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ticagrelor (prevention of atherothrombotic events after myocardial infarction) – Addendum to Commission A16-15]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ticagrelor (new therapeutic indication): benefit assessment according to §35a Social Code Book V]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ticagrelor - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Thrombectomy for ischaemic stroke: patient characteristics, structural requirements and (differential) diagnostics]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Thresholds for responder analyses of complex scales in benefit assessments – the 15% approach]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Three-dimensional stereoscopic vision system laparoscopy using monitors in gastroenterological, thoracic, urologic and gynecological conditions]
2010     Committee for New Health Technology Assessment (CNHTA) [Thoracoscopic epicardial radiofrequency ablation for atrial fibrillation]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Thioridazine for the treatment of behavior disorders in patients with intellectual disability]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Thiopurine-methyltransferase genotyping prior to thiopurine therapy]
2009     Committee for New Health Technology Assessment (CNHTA) [ThinPrep liquid-based aspiration cytopathology test]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Thiazolidinediones for type 2 diabetes mellitus]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Thiazolidinediones for type 2 diabetes mellitus]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Thiazolidinediones for the treatment of type 2 diabetes mellitus]
2012     Basque Office for Health Technology Assessment (OSTEBA) [They just told me I have diabetes! Guide for youth and adults with type 1 diabetes and in intensive treatment]
2025     Agencia de Evaluacion de Tecnologias Sanitarias (AETS-ISCIII) [Thermotest for the assessment of small fibre neuropathy]
2010     Committee for New Health Technology Assessment (CNHTA) [Thermoregulatory sweat test]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Therapy of the burnout syndrome]
1994     Basque Office for Health Technology Assessment (OSTEBA) [Therapy for benign prostatic hyperplasia]
2025     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Therapeutic use of blankets, vests and other weighted objects with different clienteles]
2009     Committee for New Health Technology Assessment (CNHTA) [Therapeutic temperature management with endovascular cooling catheter]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Therapeutic strategies in refractory schizophrenia or treatment resistant schizophrenia]
2012     Canary Health Service [Therapeutic management of retinitis pigmentosa]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Therapeutic management of colorectal cancer patients with liver metastases based on the presence of disseminated tumor cells in bone marrow]
2007     Canary Health Service [Therapeutic interventions in the treatment of mental illness in children]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Therapeutic hypothermia in patients with stroke or brain trauma]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Therapeutic hypothermia in patients who underwent cardiac arrest resuscitation]
2009     The Swedish Council on Health Technology Assessment (SBU) [Therapeutic hypothermia following perinatal asphyxia]
2025     HTA Region Stockholm [Therapeutic benefits and adverse effects of extended idebenone treatment in Leber hereditary optic neuropathy (LHON)]
2009     Committee for New Health Technology Assessment (CNHTA) [The vest airway clearance system]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [The value of F-18-fluorodeoxyglucose positron emission tomography for detection of metastatic infectious foci complicating Gram-positive bacteremia (MI-PET)]
2024     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [The utility of neuropsychological tests for the detection and diagnosis of frontotemporal dementia (FTD)]
2022     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [The use of social media and electronic communication in the delivery of youth protection services to young people in difficulty and their families]
2025     The Danish Health Technology Council (DHTC) [The use of point of care tests (POCT) for elderly patients at home]
2001     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [The use of neuroimaging in dementia evaluation. A medical technology report]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [The use of liquid based cytology (LBC) and conventional pap smear (CPS) for cervical screening in Denmark]
2001     Basque Office for Health Technology Assessment (OSTEBA) [The use of inhalation chambers in the treatment of infantile asthma]
2020     HTA South [The use of hydrogel spacer in radiotherapy of prostate cancer]
2009     Technology Assessment Unit of the McGill University Health Centre (MUHC) [The use of carmustine implants (Gliadel wafers) in patients with malignant glioma]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [The use of autologous cord blood for anemia of prematurity]
2024     Basque Office for Health Technology Assessment (OSTEBA) [The use of artificial intelligence in breast cancer screening programmes]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [The treatment of parkinson's disease with dopamine agonists]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [The treatment of depression in primary care: the efficiency of computerised cognitive behaviour therapy]
2010     National Evidence-based Healthcare Collaborating Agency (NECA) [The survey and cross-sectional analysis of palliative radiotherapy for bone metastases to facilitate its proper use in cancer patients]
2015     National Evidence-based Healthcare Collaborating Agency (NECA) [The status and dissemination plan of clinical practice guidelines in Korea]
2009     Andalusian Health Technology Assessment Area (AETSA) [The state of research into inequalities in the incidence, death, prevention and healthcare in cancer in Spain. A bibliometric study and literature review.]
2004     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [The screening of congenital adrenal hyperplasia. Applicability in Galicia]
2009     Norwegian Knowledge Centre for the Health Services (NOKC) [The scientific knowledge base for treatment of patients with cleft lip, alveolus and palate]
2025     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [The safety, efficacy, effectiveness, efficiency, and organizational impact of mHealth tools for guided telerehabilitation that enable telemonitoring in neck pain, low back pain, and painful shoulder]
2005     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [The role of vascular endoprostheses in the treatment of intracranial aneurysms]
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [The role of occupational exposures in the development of cancer among firefighters]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [The role of homocysteine as a predictor for coronary heart disease]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [The role of homocysteine as a predictor for coronary heart disease]
2009     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [The relevance of the neonatal urine screening for inborn errors of metabolism performed in Quebec]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [The relevance of intraperitoneal chemotherapy in preventing or treating neoplasms of the peritoneal surfaces - peritoneal metastases secondary to ovarian cancer]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [The relevance of intraperitoneal chemotherapy in preventing or treating neoplasms of the peritoneal surfaces - peritoneal mesothelioma]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [The relevance of hearing screening for workers in the Quebec context]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [The relationship between the cost-effectiveness of blood safety measures and the distribution of patients receiving blood]
2007     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [The practice of percutaneous coronary interventions in hospitals without on-site cardiac surgery: review of guidelines and analysis of Quebec data, 1999-2004]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [The potential influence of socio-demographical factors on access to and results of rehabilitation]
2012     Haute Autorite de sante (HAS) [The place of and conditions for carrying out polysomnography and respiratory polygraphy in sleep disorders]
2004     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [The most often used androgen receptor blockers (flutamide, bicalutamide, nilutamide) in prostate cancer; systematic review of the clinical and economic literature]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [The mortality rate and medical costs identified by a national health examination analysis]
2024     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [The mental health day hospital: drawing on the literature to define the service offer and enhance practice]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [The Measles-Mumps-Rubella vaccination from a health political and economical point of view]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [The measels-mumps-rubella vaccination from a health political and economical point of view]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [The Mandometer method versus conventional treatment; predictors of early treatment efficacy and relapse in anorexia nervosa patients treated with the Mandometer method or conventional treatment]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [The Manchester triage system in paediatric emergency care]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [The long run - short run efficiency paradox in health care]